71 results
6-K
EX-99.1
GLPG
Galapagos NV
3 May 24
Galapagos reports first quarter 2024 financial results
9:30am
, recruitment of patients, product development activities and regulatory approval requirements (including the risk that data from our ongoing and planned
6-K
EX-99.1
GLPG
Galapagos NV
8 Apr 24
Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
9:27am
, including the expected recruitment for such trials. Forward-looking statements involve known and unknown risks, uncertainties and other factors which might
6-K
EX-99.2
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
or at all, the inherent risks and uncertainties associated with competitive developments, clinical trials, recruitment of patients, estimated patient … leukemia (rrCLL) and Richter transformation (RT) (cut-off date: 6 September 2023) Patient recruitment of the Phase 1 dose-finding part of EUPLAGIA-1
6-K
EX-99.15
GLPG
Galapagos NV
29 Mar 24
Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
5:03pm
Base salary Fixed pay reflects the role, skills, experience and contribution to the Company and is set at levels that support the recruitment
6-K
EX-99.1
17b8pjc6s xp1i0wb
23 Feb 24
Galapagos announces full year 2023 results and outlook for 2024
6:41am
6-K
EX-99.1
1ckfsh64k
16 Feb 24
Galapagos presents at EBMT-EHA annual meeting 2024
6:00am
6-K
EX-99.1
bxtd7xeu
21 Dec 23
Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
4:03pm
6-K
EX-99.1
9rbl4w74
12 Dec 23
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
7:02am
6-K
EX-99.1
9276v2h13ai mdht3m
12 Dec 23
Current report (foreign)
6:00am
6-K
EX-99.1
l4pd4ucdky675v88yj
3 Nov 23
Galapagos reports third quarter 2023 results and releases new encouraging data from CAR-T studies for presentation at ASH 2023
8:26am
6-K
EX-99.1
n2g0hqnhwf4zdo
30 Aug 23
Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with active systemic lupus erythematosus
6:31am
6-K
EX-99.1
wfb pbv6fh
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.2
2xe5w49n9sufkmg3k3si
4 Aug 23
Galapagos announces first half-year 2023 financial results
4:05pm
6-K
EX-99.1
a3h40 c2qkfsj1
12 Jun 23
Current report (foreign)
7:32am
6-K
EX-99.1
t8k z8jczjqczcja4r
23 May 23
Galapagos demonstrates commitment to immunology with new data in rheumatoid arthritis at EULAR 2023
7:30am
6-K
EX-99.1
hvphd4ap h9w7kmo
5 May 23
Galapagos announces first quarter 2023 financial results
4:05pm
6-K
EX-99.1
y5r h2y3jypeqzs
2 May 23
Galapagos announces departure of Bart Filius, Chief Operating Officer and Chief Financial Officer
4:49pm
6-K
EX-99.1
6zddqkyraaoh6 pe5
13 Dec 22
Galapagos and CellPoint presented encouraging initial data at ASH 2022 for GLPG5101, a CD19 CAR-T candidate manufactured at point-of-care
7:49am
6-K
EX-99.1
pqb8f9
7 Nov 22
Galapagos announces strategy to accelerate innovation and reports strong third quarter 2022 results
6:08am